Danni Colledge
Royal Melbourne Hospital
32 Papers
465 Citations
Danni Colledge is an academic researcher from Royal Melbourne Hospital. The author has contributed to research in topics: Hepatitis B virus & HBeAg. The author has an hindex of 17, co-authored 32 publications. Previous affiliations of Danni Colledge include Fairfield Hospital.
Chat about Author
Papers
Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro
William E. Delaney,Ros Edwards,Danni Colledge,Tim Shaw,Phil Furman,George R. Painter,Stephen Locarnini +6 more
TL;DR: The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication that inhibited the replication of wild-type HBV with 50% inhibitory concentrations.
168
Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
TL;DR: The results suggest that combinations of 3TC and PCV may act synergistically against HBV in vivo, and the combination was more effective in reducing the normally recalcitrant viral covalently closed circular DNA form of DHBV than either drug alone.
115
Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus
William E. Delaney,Ros Edwards,Danni Colledge,Tim Shaw,Joseph Torresi,Thomas G. Miller,Harriet C. Isom,C.-Thomas Bock,Michael P. Manns,Christian Trautwein,Stephen Locarnini +10 more
TL;DR: The utility of the HBV-baculovirus system as an in vitro tool for the molecular characterization of clinically significant HBV strains is confirmed and supported by the limited amount of clinical data currently available.
103
In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir
TL;DR: The anti-DHBV effects of all the combinations containing PCV, 3TC, and PMEA are greater than that of each of the individual components and that their combined activities are approximately additive or synergistic.
97
Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.
Alexander J. Thompson,Danni Colledge,S. Rodgers,R. Wilson,Peter Revill,Paul V. Desmond,Ashley Mansell,Kumar Visvanathan,Stephen Locarnini +8 more
TL;DR: Data support an active role for hepatocytes in inhibiting HBV replication and provide a rationale for the development of TLR agonists as potentially novel antiviral agents.
66